TNGX on Nasdaq

Tango Therapeutics (United States)

American pharmaceutical preparations company based in Boston, founded in 2017.1

Price unavailable

Last updated Oct 18, 2026.

Overview

2017Founded1

Compare with Nuvation Bio Inc., Fortress Biotech or Journey Medical Corp, or pick any stock.

  • TickerTNGX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersDE1
  • Websitewww.tangotx.com
  • Incorporated inDE3
  • Business address201 Brookline Avenue, Suite 901, Boston, Ma 022153
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-178.4%Operating margin4
-162.9%Net margin4
48.3%Revenue growth, 20254
-29.3%Return on equity4
-$139.9MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$132.2M
  • Income tax0¢$4.0K

Out of $62.4M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$62.4M in 2025+715% since 2020
0$20.0M$40.0M$60.0M$80.0M2020: $7.7M$7.7M20202021: $37.0M$37.0M2021+384%2022: $24.9M$24.9M2022−33%2023: $36.5M$36.5M2023+47%2024: $42.1M$42.1M2024+15%2025: $62.4M$62.4M2025+48%
Operating income5674-$111.3M in 2025+113% since 2020
-$150.0M-$100.0M-$50.0M02020: -$52.2M-$52.2M20202021: -$58.2M-$58.2M2021+11%2022: -$111.1M-$111.1M2022+91%2023: -$114.2M-$114.2M2023+3%2024: -$145.6M-$145.6M2024+28%2025: -$111.3M-$111.3M2025−24%
Net income5674-$101.6M in 2025+95% since 2020
-$150.0M-$100.0M-$50.0M02020: -$52.0M-$52.0M20202021: -$58.2M-$58.2M2021+12%2022: -$108.2M-$108.2M2022+86%2023: -$101.7M-$101.7M2023−6%2024: -$130.3M-$130.3M2024+28%2025: -$101.6M-$101.6M2025−22%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Total Revenue$62.4M$42.1M$36.5M
Research and development$132.2M$143.9M$115.2M
General and administrative$41.5M$43.7M$35.5M
Total operating expenses$173.7M$187.7M$150.7M
Loss from operations-$111.3M-$145.6M-$114.2M
Interest income$5.6M$7.9M$6.6M
Other income, net$4.1M$7.6M$5.9M
Total other income, net$9.7M$15.5M$12.6M
Loss before income taxes-$101.6M-$130.1M-$101.6M
Provision for income taxes-$4.0K-$208.0K-$134.0K
Net loss-$101.6M-$130.3M-$101.7M
Net loss per common share - basic-$0.87-$1.19-$1.08
Net loss per common share - diluted-$0.87-$1.19-$1.08
Weighted average number of common shares outstanding - basic116.2M shares109.2M shares94.6M shares
Weighted average number of common shares outstanding - diluted116.2M shares109.2M shares94.6M shares
Unrealized (loss) gain on marketable securities-$112.0K$150.0K$3.9M
Comprehensive loss-$101.7M-$130.2M-$97.9M

Compare Tango Therapeutics (United States) with another company

Leadership

Who has led Tango Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Aaron I. Davis2020
  2. Barbara Weber2021–2025
  3. Malte Peters2026–now

Chair

  1. Barbara Weber2026–now

President

  1. Christopher Fuglesang2020
  2. Malte Peters2026
  3. Adam Crystal2026–now

Chief financial officer

  1. Michael Beauchamp2020
  2. Daniella Beckman2021–2026
  3. Matthew Gall2026–now

Chief operating officer

  1. Andrew Ruel Ellis2020
20202025
Board members and other officers (22)

Former names

  • BCTG Acquisition Corp.Jul 30, 2020 to Aug 9, 20213

Timeline

  1. Jan 12, 2026New chief executive Malte Peters becomes CEO11
  2. Aug 12, 2021New chief executive Barbara Weber becomes CEO12
  3. Sep 3, 2020New chief executive Aaron I. Davis becomes CEO13
  4. 2017Founded Founded1

Filings

349 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 45 major events, 124 insider forms, 62 large holders, 2 private raises, 96 other. The latest 20:

  1. Oct 5, 20264 EDGAR
  2. Sep 24, 20264 EDGAR
  3. Sep 22, 2026144 EDGAR
  4. Sep 3, 20264 EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 14, 2026SCHEDULE 13G EDGAR
  10. Aug 12, 2026SCHEDULE 13G/A EDGAR
  11. Aug 11, 20268-K EDGAR
  12. Aug 11, 2026424B5 EDGAR
  13. Aug 11, 20268-K EDGAR
  14. Aug 11, 202610-Q EDGAR
  15. Aug 7, 20268-K/A EDGAR
  16. Aug 6, 20268-K EDGAR
  17. Aug 5, 20264 EDGAR
  18. Aug 3, 2026144 EDGAR
  19. Jul 2, 20264 EDGAR
  20. Jun 23, 20264 EDGAR

The 349 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 62 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13G/A
  2. Aug 14, 2026SCHEDULE 13G/A
  3. Aug 14, 2026SCHEDULE 13G/A
  4. Aug 14, 2026SCHEDULE 13G/A
  5. Aug 14, 2026SCHEDULE 13G
  6. Aug 12, 2026SCHEDULE 13G/A
  7. May 15, 2026SCHEDULE 13G/A
  8. May 15, 2026SCHEDULE 13G
  9. May 15, 2026SCHEDULE 13G/A
  10. May 15, 2026SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 24, 2025Raised $15 million in a private offering of equity Form D: 1 investor so far Form D
  2. Aug 11, 2023Raised $80 million in a private offering of equity Form D: 17 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Rtw Investments, LP13,900,620$434.5M3.7%+600,000
BlackRock, Inc.12,438,444$388.8M0.0%+3,690,399
Fmr LLC12,333,339$385.5M0.0%+2,427,420
Farallon Capital Management, L.l.c.12,277,000$383.8M2.3%+3,179,589
Boxer Capital Management, LLC10,876,219$340.0M25.6%No change
Goldman Sachs Group Inc9,980,620$312.0M0.0%+4,904,228
TCG Crossover Management, LLC9,081,201$283.9M6.8%−1,449,870
Paradigm Biocapital Advisors LP6,357,523$198.7M3.7%+2,347,844
Siren, L.L.C.6,179,364$193.2M3.9%+522,259
State Street Corp5,979,806$186.9M0.0%+1,327,912
Vanguard Capital Management LLC5,957,348$186.2M0.0%+795,917
Adage Capital Partners Gp, L.l.c.5,600,000$175.1M0.2%−7,209,485
Jupiter Topco LLC5,056,352$158.0M0.1%New
Deep Track Capital, LP4,200,000$131.3M1.9%+1,450,000
Deerfield Management Company, L.P.4,190,611$131.0M1.6%+43,798
Woodline Partners LP4,000,567$125.1M0.4%−3,999,446
Trv Gp Iv, LLC6,374,574$120.2M47.4%No change
Geode Capital Management, LLC3,742,791$117.0M0.0%+1,067,014
Perceptive Advisors LLC3,377,000$105.6M1.6%+2,568,847
Seven Fleet Capital Management LP3,228,144$95.7M15.8%+2,726,132
Logos Global Management LP2,850,000$89.1M3.8%−150,000
Caligan Partners LP2,500,103$78.2M3.8%+91,305
Holocene Advisors, LP2,410,939$75.4M0.2%−1,521,664
Commodore Capital LP2,250,000$70.3M4.2%New
Balyasny Asset Management L.P.2,016,379$63.0M0.1%−1,810,280

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39